Inspire respiratory drugs
Executive Summary
Genentech returns rights for development drugs INS365 for chronic bronchitis and INS37217 for cystic fibrosis and chronic sinusitis to Durham, N.C.-based Inspire Pharmaceuticals. Inspire does not plan to seek another U.S. marketing partner for the products. Company will reevaluate the protocol for Phase II trials for chronic bronchitis in July; trials were halted April 2000 due to inadequate design